HSBC Holdings
CCCC icon

HSBC Holdings’s C4 Therapeutics CCCC Stock Holding History

HSBC Holdings’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.3K Hold
13,629
– – ﹤0.01% 2834
2026
Q1 		$36K Hold
13,629
– – ﹤0.01% 2830
2025
Q4 		$26.2K Hold
13,629
– – ﹤0.01% 2893
2025
Q3 		$30.1K Sell
13,629
-11,528
-46% -$27.7K ﹤0.01% 2665
2025
Q2 		$35.6K Sell
25,157
-330
-1% -$480 ﹤0.01% 2956
2025
Q1 		$41.3K Buy
25,487
+6,128
+32% +$18.3K ﹤0.01% 2927
2024
Q4 		$68.3K Sell
19,359
-1,809
-9% -$8.99K ﹤0.01% 2952
2024
Q3 		$123K Buy
+21,168
New +$127K ﹤0.01% 2760
2024
Q1 		– Sell
-30,200
Closed -$171K – 3069
2023
Q4 		$171K Sell
30,200
-2,453
-8% -$5.59K ﹤0.01% 2510
2023
Q3 		$62K Hold
32,653
– – ﹤0.01% 2606
2023
Q2 		$90.3K Buy
32,653
+13,893
+74% +$44.7K ﹤0.01% 2444
2023
Q1 		$60.1K Buy
18,760
+8,605
+85% +$50.7K ﹤0.01% 2553
2022
Q4 		$58.9K Buy
+10,155
New +$84.2K ﹤0.01% 2954
2022
Q2 		– Sell
-10,275
Closed -$251K – 3261
2022
Q1 		$251K Buy
+10,275
New +$250K ﹤0.01% 2870

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HSBC Holdings's CCCC Position: Q2 2026 in Review

HSBC Holdings held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 13,629 shares worth $70.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

HSBC Holdings first reported a position in CCCC in Q1 2022 and has held it in 14 quarters since. The position peaked at $251K in Q1 2022. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • HSBC Holdings held 13,629 shares of C4 Therapeutics worth $70.3K as of Q2 2026.
  • HSBC Holdings left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2834 holding.
  • HSBC Holdings first reported a position in C4 Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • HSBC Holdings's C4 Therapeutics position peaked at $251K in Q1 2022.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.